Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02357836
• Other study ID #: STU 122014-038
• Status: Completed
• Phase: Early Phase 1
• Start date: June 2015
• Est. completion date: July 2018

Study information

• Verified date: April 2021
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.

Description:

This is a phase 0 clinical trial. While clinical data including safety will be recorded, the principal outcomes are pharmacodynamic endpoints. Specifically, the investigators seek to identify: (1) effects of itraconazole on tumor angiogenesis, (2) effects of itraconazole on the Hh pathway, (3) biomarker predictors of these effects, (4) the correlation between itraconazole pharmacokinetics and these effects, (5) the correlation between different biomarkers. Up to 15 eligible patients with previously diagnosed or suspected NSCLC planned for resection will undergo a study-specific core needle biopsy, imaging (dynamic contrast enhanced [DCE]-, diffusion weighted imaging [DWI]-, and arterial spin labeling [ASL] magnetic resonance imaging [MRI]), skin punch biopsy, and collection of peripheral blood. Subjects will then receive itraconazole 600 mg PO daily for 7-10 days, following which they will undergo repeat imaging, skin biopsy, and blood collection. Subsequently they will undergo surgical resection. Due to the safety profile of itraconazole when used as an antifungal agent , all histologic subtypes of NSCLC will be eligible for the trial. The itraconazole dose of 600 mg, higher than an anti-angiogenic dose, has been shown to inhibit the Hedgehog (Hh) pathway.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically proven NSCLC planned for surgical resection. All NSCLC histologic subtypes are eligible. Alternatively, patients in whom a diagnosis of NSCLC is highly suspected based on history and imaging studies and who are, therefore, scheduled for diagnostic biopsy and/or surgical resection will also be eligible for screening, enrollment, and study treatment if they meet all additional eligibility criteria. In the event that biopsies do not confirm NSCLC, such patients will be removed from study but monitored for any adverse events resulting from study participation.

2. No prior therapy but planned for surgical resection

3. Age = 18 years.

4. ECOG (Eastern Cooperative Oncology Group) 0-2 performance status

5. Adequate organ function as defined below:

• total bilirubin within normal institutional limits
• AST (Aspartate Aminotransferase) (SGOT)/ALT (Alanine Aminotransferase) (SPGT) = 2.5 X institutional upper limit of normal
• creatinine = 2 X institutional upper limit of normal

6. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 6.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who

meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

7. Ability to understand and willingness to sign a written informed consent.

Exclusion Criteria:

1. Subjects may not be receiving any investigational agents that would confound interpretation of study pharmacodynamic endpoints.

2. History of allergic reactions attributed to itraconazole or to compounds of similar chemical or biologic composition to itraconazole.

3. Uncontrolled, concurrent medical illness.

4. Active hepatitis or symptomatic liver disease.

5. History of or current evidence of uncontrolled cardiac ventricular dysfunction (congestive heart failure) or NYHA (New York Heart Association) Class III or IV heart failure.

6. Current use of medications significantly affecting metabolism of itraconazole (certain anti-convulsants, corticosteroids). See 3.5 Drug Interactions in protocol.

7. Current evidence of hyperthyroidism (which would increase metabolism of itraconazole).

8. Pregnant or lactating female or any female trying to get pregnant.

9. Claustrophobia that would interfere with MRI studies anticipated to last 45-50 minutes.

10. Metal implants deemed at risk for migration during MRI studies.

11. CrCl (Creatinine clearance) < 45 mL/min (increased risk of nephrogenic systemic fibrosis [NSF] from MRI Gadolinium contrast).

12. Known allergy to MRI contrast.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Itraconazole
Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure.

Locations

Country	Name	City	State
United States	UT Southwestern Medical Center	Dallas	Texas

Sponsors (2)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Tumor Tissue Microvessel Density [MVD] From Baseline	Images of DAPI (4',6-Diamidino-2-Phenylindole) , CD31 (cluster of differentiation 31 ), and CD34 (cluster of differentiation 34) were taken from the same field of view and then merged.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in HIF1a From Baseline	A commercially available kit will be used to measure HIF1a levels.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in VEGFR2 From Baseline	A commercially available kit will be used to measure VEGFR2 levels.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in Phospho-VEGFR2 From Baseline	A commercially available kit will be used to measure Phospho-VEGFR2 levels.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Mean Percent Change in Other Plasma Cytokine From Baseline to Post-Treatment	The following plasma cytokines were measured using a commercially available kit.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Mean Percent Change in Angiogenic Cytokines From Baseline	A commercially available kit will be used to measure Angiogenic Cytokines levels.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Changes in Perfusion (Ktrans)	DCE (dynamic contrast enhanced ) MRI is an established technology to assess microvessel density (MVD) and tumor capillary permeability.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Number of Participants With Tumor SMO (Smoothened) Gene Mutations, GLI2 and CCND1 Copy Number, PI3K-mTOR Pathway Activation	phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (PI3K-mTOR pathway )	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in Tumor Tissue GLI1, SHH and PTCH1 Levels From Baseline	This can be measured by analyzing frozen-treated tumor tissue for GLI1 (glioma-associated oncogene ) and PTCH1(patched-1) mRNA (Messenger Ribonucleic Acid) by qPCR.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in Skin Biopsy GLI1 Levels From Baseline	We analyzed serial skin biopsies for GLI1 mRNA by qPCR (quantitative polymerase chain reaction).	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in Skin Biopsy SHH Levels From Baseline	We analyzed serial skin biopsies for SHH (Sonic Hedgehog )levels mRNA by qPCR.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Change in Skin Biopsy PTCH1 Levels From Baseline	We analyzed serial skin biopsies for PTCH1 mRNA by qPCR.	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Number of Participants With Tumor Cell Proliferation/Apoptosis	Tumor proliferation and apoptosis will be assessed by tumor Ki67 and cleaved caspase 3 levels	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Itraconazole Levels in Post-treatment Serum	Itraconazole levels assessed by post-treatment serum	Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Itraconazole Levels in Tumor Tissue	Itraconazole levels assessed by tumor tissue	Baseline and Post Treatment (after 7-10 days of itraconazole bid)
Secondary	Itraconazole Levels in Skin Biopsy	Itraconazole levels assessed by skin biopsy	Baseline and Post Treatment (after 7-10 days of itraconazole bid)